6. (New) The composition of Claim 4, wherein the amino acid sequence of the immunogenic peptide comprises SEQ ID NOS: 1 and 2.

7. (New) The composition of Claim 4, wherein the pharmaceutically acceptable carrier comprises liposomes, colloidal gold, and carrier proteins.

8. (New) The composition of Claim 7, wherein the carrier protein comprises maltose binding protein, bovine serum albumin, keyhole lympet hemocyanin, ovalbumin, flagellin, thyroglobulin, serum albumin, gamma globulin, syngeneic cells, and polymers of D- and/or L-amino acids.

9. (New) The composition of Claim 7, further comprising adjuvants, preservatives, diluents, emulsifiers, and stabilizers.

10. (New) The composition of Claim 9, wherein the adjuvant is selected from the group consisting of lipophilic muramyl dipeptide derivatives, nonionic block polymers, aluminum hydroxide, aluminum phosphate, lipid A, Freund's incomplete adjuvant, Freund's complete adjuvant, polydispersed ß-(1,4) linked acetylated mannan, polyoxyethylene-polyoxypropylene copolymer adjuvants, saponin derivative adjuvants, killed *Bordetella pertussis*, lipopolysaccharide of gram-negative bacteria, polymeric anions, dextran sulfate, inorganic gels, alum, aluminum hydroxide, and aluminum phosphate.

11. (New) The composition of Claim 4, further comprising a hydrophobic moiety attached to the immunogenic peptide.

12. (New) The composition of Claim 11, wherein the hydrophobic moiety comprises at least one long chain fatty acid having at least 10 carbon atoms in the lipid backbone.

13. (New) The composition of Claim 11, wherein the hydrophobic moiety is selected from the group consisting of palmitic acid, stearic acid, myristic acid, lauric acid, oleic acid, linoleic acid, and linolenic acid.

14. (New) An immunogenic composition comprising,

(a) an immunogenic peptide fragment of vascular endothelial growth factor; and

(b) a pharmaceutically acceptable carrier.

15. (New) The composition of Claim 14, wherein the immunogenic peptide fragment corresponds to the receptor binding domain of vascular endothelial growth factor.

16. (New) The composition of Claim 14, wherein the amino acid sequence of the immunogenic peptide comprises SEQ ID NOS: 3-9.

17. (New) The composition of Claim 14, wherein the pharmaceutically acceptable carrier comprises liposomes, colloidal gold, and carrier proteins.

18. (New) The composition of Claim 17, wherein the carrier protein comprises maltose binding protein, bovine serum albumin, keyhole lympet hemocyanin, ovalbumin, flagellin, thyroglobulin, serum albumin, gamma globulin, syngeneic cells, and polymers of D- and/or L-amino acids.

19. (New) The composition of Claim 17, further comprising adjuvants, preservatives, diluents, emulsifiers, and stabilizers.

20. (New) The composition of Claim 19, wherein the adjuvant is selected from the group consisting of lipophilic muramyl dipeptide derivatives, nonionic block polymers, aluminum hydroxide, aluminum phosphate, lipid A, Freund's incomplete adjuvant, Freund's complete adjuvant, polydispersed ß-(1,4) linked acetylated mannan, polyoxyethylene-polyoxypropylene copolymer adjuvants, saponin derivative adjuvants, killed *Bordetella pertussis*, lipopolysaccharide of gram-negative bacteria, polymeric anions, dextran sulfate, inorganic gels, alum, aluminum hydroxide, and aluminum phosphate.

21. (New) The composition of Claim 14, further comprising a hydrophobic moiety attached to the immunogenic peptide.

22. (New) The composition of Claim 21, wherein the hydrophobic moiety comprises at least one long chain fatty acid having at least 10 carbon atoms in the lipid backbone.

23. (New) The composition of Claim 21, wherein the hydrophobic moiety is selected from the group consisting of palmitic acid, stearic acid, myristic acid, lauric acid, oleic acid, linoleic acid, and linolenic acid.

24. (New) An immunogenic composition comprising,

(a) an immunogenic peptide fragment of fibroblast growth factor and vascular endothelial growth factor; and

(b) a pharmaceutically acceptable carrier.

25. (New) The composition of Claim 24, wherein the immunogenic peptide fragment of fibroblast growth factor corresponds to the heparin binding domain of fibroblast growth factor, and the immunogenic peptide fragment of vascular endothelial growth factor corresponds to the receptor binding domain of vascular endothelial growth factor.

26. (New) The composition of Claim 25, wherein the pharmaceutically acceptable carrier comprises liposomes, colloidal gold, and carrier proteins.

27. (New) The composition of Claim 26, wherein the carrier protein comprises maltose binding protein, bovine serum albumin, keyhole lympet hemocyanin, ovalbumin, flagellin, thyroglobulin, serum albumin, gamma globulin, syngeneic cells, and polymers of D- and/or L-amino acids.

28. (New) The composition of Claim 26, further comprising adjuvants, preservatives, diluents, emulsifiers, and stabilizers.

29. (New) The composition of Claim 28, wherein the adjuvant is selected from the group consisting of lipophilic muramyl dipeptide derivatives, nonionic block polymers, aluminum hydroxide, aluminum phosphate, lipid A, Freund's incomplete adjuvant, Freund's complete adjuvant, polydispersed ß-(1,4) linked acetylated mannan, polyoxyethylene-polyoxypropylene copolymer adjuvants, saponin derivative adjuvants, killed *Bordetella pertussis*, lipopolysaccharide of gram-negative bacteria, polymeric anions, dextran sulfate, inorganic gels, alum, aluminum hydroxide, and aluminum phosphate.

30. (New) A method for treating cancer or hyperproliferative disorders in a human or animal comprising administering to the human or animal an effective amount of a composition comprising an immunogenic peptide fragment of fibroblast growth factor and a pharmaceutically acceptable carrier.

31. (New) The method of Claim 30, wherein the immunogenic peptide fragment corresponds to the heparin binding domain of fibroblast growth factor.

32. (New) The method of Claim 30, wherein the amino acid sequence of the immunogenic peptide fragment comprises SEQ ID NOS: 1 and 2.

33. (New) The method of Claim 30, wherein the pharmaceutically acceptable carrier comprises liposomes, colloidal gold, and carrier proteins.

34. (New) The method of Claim 30, wherein the carrier protein comprises maltose binding protein, bovine serum albumin, keyhole lympet hemocyanin, ovalbumin, flagellin, thyroglobulin, serum albumin, gamma globulin, syngeneic cells, and polymers of D- and/or L-amino acids.

35. (New) The method of Claim 30, further comprising adjuvants, preservatives, diluents, emulsifiers, and stabilizers.

36. (New) The method of Claim 30, wherein the hyperproliferative disorder comprises hemangioma, solid tumors, blood borne tumors, leukemia, metastasis, telangiectasia, psoriasis, scleroderma, pyogenic granuloma, myocardial angiogenesis, Crohn's disease, plaque neovascularization, arteriovenous malformations, corneal diseases, rubeosis, neovascular glaucoma, diabetic retinopathy, retrolental fibroplasia, arthritis, diabetic neovascularization, macular degeneration, wound healing, peptic ulcer, Helicobacter related diseases, fractures, keloids, vasculogenesis, hematopoiesis, ovulation, menstruation, placentation, and cat scratch fever.

37. (New) A method for treating cancer or hyperproliferative disorders in a human or animal comprising administering to the human or animal an effective amount of a composition comprising an immunogenic peptide fragment of vascular endothelial growth factor and a pharmaceutically acceptable carrier.

38. (New) The method of Claim 37, wherein the immunogenic peptide fragment corresponds to the receptor binding domain of vascular endothelial growth factor.

39. (New) The method of Claim 37, wherein the amino acid sequence of the immunogenic peptide fragment comprises SEQ ID NOS: 3-9.

40. (New) The method of Claim 37, wherein the pharmaceutically acceptable carrier comprises liposomes, colloidal gold, and carrier proteins.

41. (New) The method of Claim 37, wherein the carrier protein comprises maltose binding protein, bovine serum albumin, keyhole lympet hemocyanin, ovalbumin, flagellin, thyroglobulin, serum albumin, gamma globulin, syngeneic cells, and polymers of D- and/or L-amino acids.

42. (New) The method of Claim 37, further comprising adjuvants, preservatives, diluents, emulsifiers, and stabilizers.

43. (New) The method of Claim 37, wherein the hyperproliferative disorder comprises hemangioma, solid tumors, blood borne tumors, leukemia, metastasis, telangiectasia, psoriasis, scleroderma, pyogenic granuloma, myocardial angiogenesis, Crohn's disease, plaque neovascularization, arteriovenous malformations, corneal diseases, rubeosis, neovascular glaucoma, diabetic retinopathy, retrolental fibroplasia, arthritis, diabetic neovascularization, macular degeneration, wound healing, peptic ulcer, Helicobacter related diseases, fractures, keloids, vasculogenesis, hematopoiesis, ovulation, menstruation, placentation, and cat scratch fever.

44. (New) A method of treating a human or animal in need of an immune response to a growth factor comprising administering to a human or animal an effective amount of a growth factor composition, wherein the composition comprises,

(a) an immunogenic peptide fragment of fibroblast growth factor; and

(b) a pharmaceutically acceptable carrier such that the composition is immunogenic for fibroblast growth factor when administered to a human or animal.

45. (New) The method of Claim 44, wherein the immunogenic peptide comprises SEQ ID NOS: 1 and 2.

46. (New) The method of Claim 44, wherein the pharmaceutically acceptable carrier comprises liposomes, colloidal gold, and carrier proteins.

47. (New) A method of treating a human or animal in need of an immune response to a growth factor comprising administering to a human or animal an effective amount of a growth factor composition, wherein the composition comprises,